|
|
Article: MIV Therapeutics' Share Price Target Projection Increased to $1.77 in New Report Update from Beacon Equity Research; Raised Share Price Target Reflects Continued Progress to Develop Breakthrough Solutions for Stents and Drug-Delivery Systems.
- Article from:
- Business Wire
- Article date:
- January 27, 2006
CopyrightCOPYRIGHT 2006 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
VANCOUVER, British Columbia -- MIV Therapeutics, Inc. (OTCBB:MIVT)(FWB:MIV), a leading developer of next-generation biocompatible coatings and advanced drug delivery systems, announced today that Beacon Equity Research, a paid investment analyst firm, has revised the Company's one year average target price projection to $1.77, representing an increase of twenty-four cents over the research firm's previous price target projection.
In addition, Beacon also estimates a substantially higher "optimal circumstances"-based share value projection target of $4.40 in the update, compared with $3.90 in its earlier, April, 2005, comprehensive paid research report.
...
Related newspaper, magazine, and journal articles:
|
|
Article: Frost & Sullivan Recognizes MIV Therapeutics for ...
Health & Medicine Week;
March 24, 2008 ;
700+ words
... ... markets, Frost & Sullivan recognizes MIV Therapeutics, Inc. (OTCBB:MIVT) (Frankfurt ... also Drugs). This Award recognizes MIV Therapeutics' development of next generation coatings ... other implantable medical devices. "MIV Therapeutics' HAp-based drug delivery systems ...
|
|